News Do the new GLP-1 “slimming” drugs deliver better pouch…
Do the new GLP-1 “slimming” drugs deliver better pouch performance?
By Red Lion Group Chair – David Davies
There have been some expansive statements about GLP-1 drugs on the J-pouch support (UK specific) Facebook forum; These sentiments and outcomes are echoed in the monthly pouch zoom forums where we occasionally hear personal testimonies from contented (and thinner) pouchees. But what are the facts behind GLP-1 use in pouchees and can the above statements be supported by real world evidence?
QUOTES FROM FACEBOOK GROUP MEMBERS
“Best 5 weeks of my life…”
“Frequency reduced from 20 times per day to 2 and from 4-6 times a night to once”
“Lost 32lbs, definitely slows the pouch output down”
“It’s slowed my pouch right down, I’d even go so far as to say I feel normal again for the first time in 25 years”
What are GLP-1 drugs and how do they work?
Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone that helps regulate blood sugar and appetite. It works by stimulating insulin secretion, inhibiting glucagon secretion, and promoting a feeling of fullness, which can help with weight management. Synthetic versions of GLP-1, full name GLP-1 receptor agonists, are prescribed in the UK for patients with type 2 diabetes and obesity, but the qualifying criteria are strict.
The most well-known brands are Mounjaro, Wegovy and Ozempic, but there are potentially many more molecules on the way – 124 in development according to one industry online platform (Fierce Biotech). Every drug company, it seems, wants a GLP-1 product in their portfolio.
Are they safe?
These class of drugs are generally considered safe. Common side effects include nausea, vomiting, diarrhoea and constipation. There is also a concern about long term effects, so people with a history of pancreatitis, for example, would be unlikely to be prescribed a GLP-1. And there are concerns that patients regain weight quickly if and when they stop taking the drug. In the UK the drugs are only available with permission from a medical doctor, who will issue a prescription only if the patient satisfies the rigorous eligibility criteria.
What are the benefits of GLP-1 drugs for pouchees?
GLP-1 drugs show promise in reducing the number of toilet visits for pouchees as well as encouraging weight loss and helping to prevent diabetes. There is also a suggestion of an anti-inflammatory effect, reducing the risk of pouchitis potentially and contributing to good pouch health. Hence the interest of pouchees in trying GLP-1s to improve their health and quality of life. The detail is contained within two recent publications in prestigious, peer-reviewed medical journals:
Doctors at the University of North Carolina in America conducted a small clinical trial of GLP-1 in pouchees who had a high frequency of bowel movements but with a normal pouch (i.e., no inflammation). The outcomes were published in the American Journal of Gastroenterology in 2024. They treated 8 pouchees with the GLP-1 drug Liraglutide (trade name Saxenda) in a well-designed, placebo-controlled, double-blind, cross-over clinical trial and showed a 35% reduction in toilet frequency on treatment compared to placebo, a reduction in urgency and better stool consistency and the drug was safe and well tolerated. The average frequency prior to treatment was 12 per day, which reduced to less than 8 per day after 1-2 weeks treatment. Treatment took place for only 2 weeks, however; it would be interesting to see if these effects became more pronounced with a longer course of treatment in pouchees.
Perhaps even more persuasive (for the regulators) is the impact of GLP-1 drug on pouchitis (inflammation of the pouch). An important publication by Aakash Desai and colleagues from various US centres appeared in the Inflammatory Bowel Diseases journal in December 2025. This was a retrospective study evaluating the outcomes of GLP-1 treatment in obese pouchees, created due to ulcerative colitis, and who had a history of recurrent pouchitis. Forty three pouchees were followed and it was found that GLP-1 treatment resulted in a decrease in the risk of recurrent pouchitis from 53% to 26%, a decreased risk of 50%. Furthermore, pouchees taking GLP-1 drugs took less antibiotics and less anti-diarrhoeal medication. This study was small and retrospective, but the outcomes suggest that GLP-1 drugs could potentially have significant health benefits for patients with recurrent pouchitis in reducing inflammation and with consequential cost savings for the health authorities.
Such studies are small and insufficient, as yet, to convince the regulators to broaden the acceptable indications to include people with a pouch. Further clinical trials are required to define the benefits and risks of taking a GLP-1 drug in the pouch population. But these early reports are promising and might pave the way for more research on GLP-1’s in pouchees, which might ultimately lead to pouchees having access to GLP-1 drugs to help with routine pouch management.
Can pouchees get GLP-1 prescribed on the NHS?
There are no regulatory approvals as yet to support the prescribing of GLP-1s to pouchees per se – only to people with diabetes and/or obesity (whether or not they have a pouch).
If you are eligible for a GLP-1 because you have one or more of the conditions for which the drug is licensed then your GP/doctor might write a prescription. Having a pouch and wanting to reduce the frequency of bowel movements per day (for example) would not qualify a patient for a prescription according to the licensed indications.
Finally, to repeat our earlier disclaimer, the Red Lion Group supports the use of GLP-1 drugs only under appropriate medical supervision.
David Davies
RLG Chairman








You must be logged in to post a comment.